3 results
Approved WMOCompleted
Primary ObjectiveThe primary objective is to assess the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill…
Approved WMOCompleted
To investigate trastuzmab-paclitaxel in EGFR-mutated NSCLC patients who have overexpression of HER2 and who have progressed on standard TKI-treatment
Approved WMOCompleted
To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE).To assess the primary bleeding events (PBE) of…